U266B1

The U266 cell line is a human multiple myeloma cell line that was established from the bone marrow of a patient with multiple myeloma. Multiple myeloma is a type of cancer that originates in plasma cells, which are a type of white blood cell present in the bone marrow. The U266 cell line has been widely used in research to study the biology of multiple myeloma, including its pathogenesis, drug sensitivity, and potential therapeutic targets.

To establish the U266 cell line, bone marrow aspirate or bone marrow samples from a patient with multiple myeloma are collected and cultured in vitro under conditions that support the growth and proliferation of the cancer cells. The cells are maintained in culture and allowed to grow and divide, forming a stable cell line that can be expanded and used for research purposes.

The U266 cell line has been instrumental in understanding the molecular mechanisms underlying multiple myeloma development and progression. Researchers have used the U266 cell line to study the genetic and epigenetic changes that drive cancer growth, as well as to test the efficacy of various therapeutic agents, including chemotherapy drugs and targeted therapies. The U266 cell line continues to be an important tool for investigating new treatment strategies for multiple myeloma and advancing our knowledge of this complex disease.